Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Trial end date:
2016-09-15
Target enrollment:
Participant gender:
Summary
This single arm, post-authorisation study is designed to evaluate the long-term safety of
pirfenidone in participants with IPF. The enrolment of participants will be completed within
approximately 24 months. Participants will receive pirfenidone according to the physician
discretion and will be followed for 2 years. Treating physicians will collect pre-specified
data at the baseline and every 3 months thereafter, for the duration of the participants'
participation in study.